the aclaris therapeutics ( n=19 ) annual annual annual annual annual annual annual annual annual annual earnings call is a transitional year in which we redefined our strategy and shifted our capital allocation to focus on our immuno-inflammatory pipeline. we reported positive results from the second of two pivotal phase 3 trials from common warts and we reported positive results from the second of two phase 3 trials from common warts. we also reported positive results from our phase 1sd/ mad trial and we are now developing a new kinase inhibitor for immuno-inflammatory diseases. we will continue to advance our additional novel kinase inhibitors, i-1777 and i-238, and we will continue to advance our additional novel  Kinase inhibitors.